A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 2Active Not RecruitingNCT05662397

HotSpot Therapeutics, Inc77 enrolled

Overview

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care. In Phase 1 patients will receive HST-1011 as either monotherapy (Parts A1 and A2) or in combination with the anti-PD1 antibody, cemiplimab (Part B1 and B2). Part A1 is a monotherapy dose escalation in which cohorts of patients will receive increasing doses of HST-1011. Upon completion of Part A1 dose escalation, an HST-1011 monotherapy dose optimization will commence (Part A2). Part B1 is a dose escalation of HST-1011 given in combination with the standard dose/regimen of cemiplimab. Dosing in Part B1 may commence prior to the completion of Part A1. Upon completion of Part B1 dose escalation, an HST-1011 dose optimization in combination with cemiplimab will commence (Part B2). Phase 2 will evaluate the preliminary antitumor activity of HST-1011 in combination with anti-PD(L)1 antibody or other standard of care therapies.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumor, Adult Relapsed Cancer Refractory Cancer

Interventions

HST-1011DRUG

HST-1011 given orally

CemiplimabBIOLOGICAL

Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Patient is at least 18 years of age. * Patient is capable of understanding and complying with protocol requirements. * Patient has signed and dated ICF. * Patient has a histologically confirmed, advanced solid tumor (metastatic, recurrent, and/or unresectable) in one of the following categories: 1) anti-PD-(L)1 relapsed/refractory; 2) platinum-resistant ovarian cancer; 4) anal cancer; 5) rectal cancer; or 6) castration-resistant prostate cancer * Patient has failed prior standard of care therapies appropriate for their metastatic disease. * Patient has at least 1 measurable non-central nervous system (CNS) lesions per RECIST 1.1. * Patient has provided consent for pre- and on-treatment biopsies. * Eastern Cooperative Performance Status of 0 or 1. Key Exclusion Criteria: * Patient has active autoimmune disease or other medical conditions requiring chronic systemic steroid therapy at the time of screening. * Patient has an unacceptable intolerance to anti-PD-(L)1 monoclonal antibody (Part B Only). * Patient has previously participated in a clinical study evaluating a CBL-B inhibitor. * Patients has untreated and/or symptomatic metastatic CNS disease. * Patient is currently taking any concomitant medications at Screening that have the potential to cause a clinically relevant drug-drug interaction with HST-1011. * Patients with a history of gastrointestinal disease that may affect absorption of the study drug, or patients who are not able to take oral medications. * Patient has an active infection requiring systemic therapy. * Patient has known or suspected infection with SARS-CoV-2 virus.

Locations (14)

Florida Cancer Specialists

Sarasota, Florida, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Memorial Sloan Kettering Cancer Center

Outcomes

Primary Outcomes

Evaluate the safety and tolerability of escalating doses of single-agent HST-1011 in Part A1 or in combination with cemiplimab in Part B1.

Number of participants with DLTs, with Adverse Events (TEAEs, SAEs), with abnormal clinically significant vital signs, Electrocardiograms (ECGs), with abnormal physical examination findings, and abnormal laboratory test results.

Time frame: 12 months

To determine the Recommended Phase 2 Dose (RP2D) and schedule of HST-1011 monotherapy in Part A2 and in combination with cemiplimab in Part B2.

Integration of safety, PD, PK, and preliminary efficacy endpoints.

Time frame: 12 months

Secondary Outcomes

Evaluate the safety and tolerability of single-agent HST-1011 in Part A2.

Number of participants with Adverse Events (TEAEs, SAEs), with abnormal clinically significant vital signs, Electrocardiograms (ECGs), with abnormal physical examination findings and abnormal laboratory test results.

Time frame: 12 months

Measurement of plasma concentrations of HST-1011 after monotherapy in Part A1 and Part A2 or in combination with cemiplimab in Part B to derive summary pharmacokinetic (PK) parameters including Tmax, Cmax, AUC0-last, Ctrough.

Characterize pharmacokinetic parameters including Tmax, Cmax, AUC0-last, Ctrough after oral administration of HST-1011 or combination of orally administered HST-1011 and IV infused cemiplimab.

Time frame: 12 months

Characterize the concentration of peripheral blood cytokines/chemokines following HST-1011 monotherapy Part A1 and Part A2, or in combination with cemiplimab in Part B1.

Measure of peripheral pharmacodynamic (PD) markers after oral administration of HST-1011 or combination of orally administered HST-1011 and IV infused cemiplimab.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.